Metastasis to gastrostomy sites from upper aerodigestive tract malignancies: a systematic review and meta-analysis.

Clicks: 250
ID: 79997
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #33 of 117 articles by views in gastrointestinal endoscopy

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Metastasis to the gastrostomy site in patients with upper aerodigestive tract (UADT) malignancies is a rare but devastating adverse event that has been poorly described. Our aim was to determine the overall incidence and clinicopathological characteristics observed with development of gastrostomy site metastasis in patients with UADT cancers.Systematic review and meta-analysis of 6,138 studies retrieved from MEDLINE, EMBASE, CINAHL, and the Cochrane Register after being queried for studies including gastrostomy site metastasis in patients with UADT malignancies.The final analysis included 121 studies. Pooled analysis showed overall event rate gastrostomy site metastasis to be 0.5% (95% CI, 0.4%-0.7%). Subgroup analysis showed an event rate of 0.56% (95% CI, 0.40%-0.79%) with the pull technique and 0.29% (95% CI, 0.15%-0.55%) with the push technique. Clinicopathological characteristics observed with gastrostomy site metastasis included: late stage disease (T3/T4) (57.8%), positive lymph node status (51.2%), and no evidence of systemic disease (M0) (62.8%) at initial presentation. Average time from gastrostomy placement to diagnosis of metastasis was 7.78 ± 4.9 months, average tumor size on detection was 4.65 (SD, 2.02) cm, and average length of survival was 7.26 (SD, 6.23) months.Gastrostomy site metastasis is a rare, but serious adverse event that occurs at an overall rate of 0.5%, particularly in patients with advanced stage disease, and is observed with a very poor prognosis. These findings emphasize a need for clinical practice guidelines to include a regular assessment of the PEG site and highlight the importance of detection and management of gastrostomy site metastasis by the multidisciplinary care oncology team.
Reference Key
siu2020metastasisgastrointestinal Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Siu, Jennifer;Fuller, Kaitlin;Nadler, Ashlie;Pugash, Robyn;Cohen, Lawrence;Deutsch, Konrado;Enepekides, Danny;Karam, Irene;Husain, Zain;Chan, Kelvin;Singh, Simron;Poon, Ian;Higgins, Kevin;Xu, Bin;Eskander, Antoine;
Journal gastrointestinal endoscopy
Year 2020
DOI
S0016-5107(20)30006-7
URL
Keywords
gastrostomy malignant seeding metastatic spread percutaneous gastrostomy upper aerodigestive tract

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.